Clinuvel Pharmaceuticals (ASX:CUV) Total Assets : A$211.68 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Assets?

Clinuvel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was A$211.68 Mil.

Warning Sign:

If a company builds assets at 41.5% a year, faster than its revenue growth rate of 25.2% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Clinuvel Pharmaceuticals's average Total Assets Growth Rate was 90.10% per year. During the past 3 years, the average Total Assets Growth Rate was 35.60% per year. During the past 5 years, the average Total Assets Growth Rate was 41.50% per year. During the past 10 years, the average Total Assets Growth Rate was 30.80% per year.

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 56.80%. The lowest was -22.90%. And the median was 4.70%.

Total Assets is connected with ROA %. Clinuvel Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was 10.79%. Total Assets is also linked to Revenue through Asset Turnover. Clinuvel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.16.

Clinuvel Pharmaceuticals Total Assets Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Assets Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Assets

Get a 7-Day Free Trial

62.35

81.54

108.57

143.95

193.71

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial															115.65	143.95	160.29	193.71	211.68

Clinuvel Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Clinuvel Pharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	164.631	+	29.082
	=	193.71

Clinuvel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	178.65	+	33.031
	=	211.68

Clinuvel Pharmaceuticals (ASX:CUV) Total Assets Explanation

Total Assets is connected with ROA %.

Clinuvel Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	21.872	/	( (193.714	+	211.681)	/ 2 )
	=	21.872	/	202.6975
	=	10.79 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Clinuvel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	32.257	/	( (193.714	+	211.681)	/ 2 )
=	32.257	/	202.6975
=	0.16

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Clinuvel Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines